10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

GAD1 Antibody (C-term) Blocking peptide

Synthetic peptide
Catalog # BP11228b

Specification

GAD1 Antibody (C-term) Blocking peptide - Product Information

Primary Accession Q99259

GAD1 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 2571

Other Names
Glutamate decarboxylase 1, 67 kDa glutamic acid decarboxylase, GAD-67, Glutamate decarboxylase 67 kDa isoform, GAD1, GAD, GAD67

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GAD1 Antibody (C-term) Blocking peptide - Protein Information

Name GAD1 (HGNC:4092)

Synonyms GAD, GAD67

Function
Catalyzes the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) with pyridoxal 5'-phosphate as cofactor.

Tissue Location
[Isoform 1]: Expressed in brain.

GAD1 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

GAD1 Antibody (C-term) Blocking peptide - Images

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

GAD1 Antibody (C-term) Blocking peptide - Background

This gene encodes one of several forms of glutamic aciddecarboxylase, identified as a major autoantigen ininsulin-dependent diabetes. The enzyme encoded is responsible forcatalyzing the production of gamma-aminobutyric acid fromL-glutamic acid. A pathogenic role for this enzyme has beenidentified in the human pancreas since it has been identified as anautoantigen and an autoreactive T cell target in insulin-dependentdiabetes. This gene may also play a role in the stiff man syndrome.Deficiency in this enzyme has been shown to lead to pyridoxinedependency with seizures. Alternative splicing of this gene resultsin two products, the predominant 67-kD form and a less-frequent25-kD form.

GAD1 Antibody (C-term) Blocking peptide - References

Lanoue, A.C., et al. Exp. Neurol. 226(1):207-217(2010)Jia, P., et al. Schizophr. Res. 122 (1-3), 38-42 (2010) :Terranova, C., et al. Alcohol 44(5):407-413(2010)Ruano, G., et al. Pharmacogenomics 11(7):959-971(2010)Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :